Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study

A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a sign...

Full description

Saved in:
Bibliographic Details
Main Authors: Svetlana V Topolyanskaya, Rachina S.A., Karine A. Lytkina, Georgiy G. Melkonyan, Yulia A Savochkina
Format: Article
Language:English
Published: Knowledge E 2024-12-01
Series:West Kazakhstan Medical Journal
Subjects:
Online Access:https://knepublishing.com/index.php/wkmj/article/view/17780
Tags: Add Tag
No Tags, Be the first to tag this record!